Peptide Atlas · Cofactor

NADH (Nicotinamide adenine dinucleotide, reduced)

In a randomized, double-blind crossover pilot study in 26 people with chronic fatigue syndrome, 8 responded to a stabilized oral form of NADH (the reduced form of nicotinamide adenine dinucleotide) against 2 on placebo.

emerging

provisional
PubChem 439153
2 citations
0 discussions
0 followers
Coenzyme I reduced
DPNH
beta-NADH
dihydronicotinamide adenine dinucleotide
reduced NAD

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- emerging
  Claim: Oral NADH in chronic fatigue syndrome: 8/26 responders versus 2/26 on placebo (pilot crossover RCT) standing
- resolved
Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome.
Forsyth LM, Preuss HG, MacDowell AL, Chiazze L, Birkmayer GD, Bellanti JA
pmid 10071523
- preclinical
  Claim: Oral NADH is degraded before it can supply nicotinamide in mice standing
- resolved
Comparison of metabolic fates of nicotinamide, NAD+ and NADH administered orally and intraperitoneally; characterization of oral NADH.
Kimura N, Fukuwatari T, Sasaki R, Shibata K
pmid 16802695

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.